<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414568</url>
  </required_header>
  <id_info>
    <org_study_id>PVAB</org_study_id>
    <nct_id>NCT02414568</nct_id>
  </id_info>
  <brief_title>Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin</brief_title>
  <acronym>PVAB</acronym>
  <official_title>A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates bendamustine in patients aged over 60 years with classical Hodgkin
      Lymphoma treated by prednisone, vinblastine and doxorubicin. 90 patients will be enrolled in
      this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The usual treatment for Hodgkin lymphoma is chemotherapy Adriamycin (also known as
      doxorubicin) + Bleomycin + Vinblastine + Dacarbazine (ABVD). Studies have shown that patients
      aged over 60 years have a lower tolerance and efficiency during this treatment than younger
      patients. There are particular pulmonary toxicities with bleomycin included in the ABVD
      treatment.

      Alternative treatment strategies have been proposed removing bleomycin in the Prednisone +
      Vinblastine + Adriamycin/Doxorubicin +Gemcitabine (PVAG) protocol evaluated in more than 60
      patients. Compared to ABVD treatment, PVAG treatment presented a more favorable toxicity
      profile. The quality of response between the two treatments is substantially equal.

      Bendamustine was evaluated in four studies in patients with Hodgkin lymphoma in relapse and
      showed higher efficacy than gemcitabine with an acceptable toxicity profile.

      In this study, the Sponsor and the coordinating investigator propose to replace dacarbazine
      in the standard ABVD protocol by bendamustine and to stop using bleomycin.

      The main objective of this study is to evaluate the safety and efficacy of bendamustine in
      patients treated with prednisone, vinblastine and doxorubicin. This is the PVAB treatment
      with which LYSARC and the coordinating investigator expect better tolerability and quality
      response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Metabolic Response rate at the end of study treatment (after 6 cycles of study treatment or at premature treatment discontinuation) defined according to Lugano Classification</measure>
    <time_frame>3 years</time_frame>
    <description>Complete Metabolic Response rate at the end of study treatment (after 6 cycles of study treatment or at premature treatment discontinuation) defined according to Lugano Classification</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility of the protocol, with adequate protocol adherence (adequate dose without excessive delay)</measure>
    <time_frame>5 years</time_frame>
    <description>Feasibility of the protocol, with adequate protocol adherence (adequate dose without excessive delay)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile including immediate toxicities and non-tumor events</measure>
    <time_frame>5 years</time_frame>
    <description>Safety profile including immediate toxicities and non-tumor events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric assessment program</measure>
    <time_frame>5 years</time_frame>
    <description>7 Quality of Life Questionnaires (QLQ)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Classical Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>PVAB regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prednisone 40 mg/m2 (PO) Days 1-5 ; Vinblastine 6 mg/m2 (IV) Day 1 ; Doxorubicin 40 mg/m2 (IV) Day 1 ; Bendamustine 120 mg/m2 (IV) Day 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine 120 mg/m2 (IV) Day 1</description>
    <arm_group_label>PVAB regimen</arm_group_label>
    <other_name>LEVACT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 40 mg/m² PO</description>
    <arm_group_label>PVAB regimen</arm_group_label>
    <other_name>CORTANCYL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vinblastine</intervention_name>
    <description>Vinblastine 6 mg/m² IV</description>
    <arm_group_label>PVAB regimen</arm_group_label>
    <other_name>VELBE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 40 mg/m² IV</description>
    <arm_group_label>PVAB regimen</arm_group_label>
    <other_name>ADRIBLASTINE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a first diagnosis of classical Hodgkin lymphoma according to the World
             Health Organization (WHO) criteria excluding nodular lymphocyte predominant subtype

          -  Age of 61 years or older

          -  No previous treatment for Hodgkin lymphoma

          -  Ann Arbor stages:

               -  II with mediastinum/thorax ≥0.33 or extranodal localization and with B symptoms

               -  Or III

               -  Or IV

          -  Baseline 18-FluoroDeoxyGlucose (FDG) PET scan (PET0) performed before any treatment
             with at least one hypermetabolic lesion

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate cardio-pulmonary function with Left Ventricular Ejection Fraction (LVEF) ≥
             50%

          -  Adequate renal function with creatinine clearance ≥ 40 mL/mn (MDRD formula)

          -  For patients aged 70 years old and more, a Mini Nutritional Assessment (MNA) ≥ 17

          -  A minimum life expectancy of 3 months

          -  Negative Human Immunodeficiency Virus, Hepatitis B (HB) Virus (anti-HB c negativity)
             and Hepatitis C Virus serologies tests ≤ 30 days before inclusion (except after
             vaccination)

          -  Having previously signed a written informed consent

          -  The patient must be covered by a social security system, if applicable

          -  Men patient must agree to use an adequate method of contraception during the study
             treatment and until 6 months after the end of the study treatment.

        Exclusion Criteria:

          -  Any other type of lymphoma including nodular lymphocyte predominant subtype

          -  Any history of treated Hodgkin lymphoma

          -  Contra-indication to any drug contained in the chemotherapy regimens

          -  Any serious active disease (according to the investigator's decision)

          -  Poor hepatic function (total bilirubin level &gt; 30 μmol/L or transaminases &gt; 2.5
             maximum normal level) unless these abnormalities are related to the lymphoma

          -  Poor bone marrow reserve as defined by leukocytes &lt; 2 G/L or platelets &lt; 100 G/L,
             unless related to bone marrow infiltration

          -  Any history of cancer during the last 3 years with the exception of non-melanoma skin
             tumors or stage 0 (in situ) cervical carcinoma. Patients previously diagnosed with
             prostate cancer are eligible if they fulfil all the followings:

               1. their disease was T1-T2a, N0, M0, with a Gleason score ≤ 7, and a prostate
                  specific antigen (PSA) ≤ 10 ng/mL prior to initial therapy,

               2. they had definitive curative therapy (i.e. prostatectomy or radiotherapy) ≥ 2
                  years before Day 1 of Cycle 1,

               3. at a minimum 2 years following therapy, they had no clinical evidence of prostate
                  cancer and their PSA was undetectable if they underwent prostatectomy or &lt; 1
                  ng/mL if they did not undergo prostatectomy

          -  Severe metabolic disease interfering with normal application of protocol treatment as
             uncontrolled diabetes mellitus leading to impossibility to perform PET scan

          -  Treatment with any investigational drug within 30 days before planned first cycle of
             chemotherapy and during the study

          -  Adult under tutelage
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hervé Ghesquières, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Lymphoma Academic Research Organisation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hervé Ghesquières, MD</last_name>
    <email>herve.ghesquieres@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>A. Z. Sint-Jan</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achiel VAN HOOF, MD</last_name>
      <email>Achiel.VanHoof@azsintjan.be</email>
    </contact>
    <investigator>
      <last_name>Achiel VAN HOOF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire St Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric VAN DEN NESTE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eric VAN DEN NESTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe BONNET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe BONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCL Mont Godinne</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc ANDRE, MD</last_name>
      <email>marc.andre@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Marc ANDRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens - Groupe Hospitalier Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre MAROLLEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre MAROLLEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrien CHAUCHET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrien CHAUCHET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier FITOUSSI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier FITOUSSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest - Hôpital Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian TEMPESCUL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adrian TEMPESCUL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gandhi Laurent DAMAJ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gandhi Laurent DAMAJ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Médipôle de Savoie</name>
      <address>
        <city>Challes les eaux</city>
        <zip>73190</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delphine SENECAL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Delphine SENECAL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Sud Francilien</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand JOLY, MD</last_name>
      <email>bertrand.joly@ch-sud-francilien.fr</email>
    </contact>
    <investigator>
      <last_name>Bertrand JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Corinne HAIOUN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Hôpital d'Enfants</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Olivier CASASNOVAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble - Hôpital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lysiane MOLINA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lysiane MOLINA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Départemental Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MORINEAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nadine MORINEAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hassan FARHAT, MD</last_name>
      <email>hfarhat@ch-versailles.fr</email>
    </contact>
    <investigator>
      <last_name>Hassan FARHAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel LARIBI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kamel LARIBI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Franck MORSCHHAUSER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed TOUATI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mohamed TOUATI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emmanuelle NICOLAS-VIRELIZIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR de Metz-Thionville - Hôpital de Mercy</name>
      <address>
        <city>Metz</city>
        <zip>57085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica MICHEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jessica MICHEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe QUITTET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe QUITTET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Claude EISENMANN, MD</last_name>
      <email>eisenmannj@ch-mulhouse.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Claude EISENMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas GASTINNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas GASTINNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal BOURQUARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pascal BOURQUARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean GABARRE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean GABARRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pauline BRICE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pauline BRICE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard DELARUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Richard DELARUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kamal BOUABDALLAH, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé GHESQUIERES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hervé GHESQUIERES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DELWAIL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincent DELWAIL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Rene Dubos</name>
      <address>
        <city>Pontoise</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo GONZALEZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hugo GONZALEZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy-Genevois - Site d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne PARRY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne PARRY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER, MD</last_name>
      <email>adelmer@chu-reims.fr</email>
    </contact>
    <investigator>
      <last_name>Alain DELMER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roch HOUOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roch HOUOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Aspasia STAMATOULLAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <email>luc-matthieu.fornecker@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Luc-Matthieu FORNECKER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marjan ERTAULT de la BRETONNIERE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marjan ERTAULT de la BRETONNIERE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine TRICOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sabine TRICOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore PERROT, MD</last_name>
      <email>au.perrot@chru-nancy.fr</email>
    </contact>
    <investigator>
      <last_name>Aurore PERROT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <last_update_submitted>March 5, 2018</last_update_submitted>
  <last_update_submitted_qc>March 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

